Hoba Therapeutics

Executive Summary

Hoba Therapeutics is a Danish early-stage biotech founded in 2017, developing novel biologic treatments for chronic pain and sensorineural hearing loss. The company's platform is based on two endogenous human neurotrophic factors, meteorin and cometin, which promote neuronal survival, regeneration, and function. These molecules offer a differentiated mechanism to address high unmet medical needs: chronic pain, where current therapies are often inadequate or addictive, and hearing loss, for which no disease-modifying drugs exist. Hoba's lead program targets chronic pain via a biologic that modulates glial cell activity and neuronal excitability, aiming to provide non-opioid relief. The hearing loss program aims to regenerate cochlear neurons and hair cells. Both programs are in preclinical development, with IND-enabling studies underway for the pain candidate. The company's science has strong rationale, but early-stage development carries significant clinical and regulatory risks. Hoba has not disclosed funding rounds, but its platform could attract partnerships with larger pharma companies seeking non-opioid pain therapies or regenerative hearing loss treatments. The company's progress toward the clinic and ability to secure financing will be key milestones in the near term.

Upcoming Catalysts (preview)

• Q1 2027IND/CTA filing for lead chronic pain candidate35% success
• Q2 2027Preclinical proof-of-concept data in hearing loss model45% success
• Q3 2027Series A or B financing round or licensing deal25% success